LONDON, Nov. 10, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its ...
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control observed in multiple patients at lowest dose ...
Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...
Potential new treatment option for multiple myeloma patients in Korea. Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 ...
The introduction of a CBG fuel option in the Victoris, likely next year, could make it the SUV with the most diverse powertrain and fuel options on our shores What the Bharat Mobility Auto Expo is to ...
RADNOR, PA & PHILADELPHIA, PA — Avantor, Inc. (NYSE: AVTR) has entered into a strategic partnership with BlueWhale Bio, a commercial-stage biotechnology firm focused on improving immune cell therapy ...
US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the first to target CS1 protein – has started recruiting patients. The multiple myeloma pipeline ...
China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these ...
Dan Neil is the author of the “Rumble Seat” column which runs Saturdays in The Wall Street Journal. Previously, Mr. Neil was the auto columnist for the Los Angeles Times from 2003 to 2010. He also ...
Not every Belgian beer style has survived the march of time. Some have disappeared as casualties of war, regulation, or changing work patterns; others have succumbed to industrial pressures or ...
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024. Regeneron is pulling the plug on an early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback